RETINAL BLOOD FLOW AFTER INTRAVITREAL BEVACIZUMAB IS A PREDICTIVE FACTOR FOR OUTCOMES OF MACULAR EDEMA ASSOCIATED WITH CENTRAL RETINAL VEIN OCCLUSION.
RETINAL BLOOD FLOW AFTER INTRAVITREAL BEVACIZUMAB IS A PREDICTIVE FACTOR FOR OUTCOMES OF MACULAR EDEMA ASSOCIATED WITH CENTRAL RETINAL VEIN OCCLUSION.
复制标题
DOI：
10.1097/iae.0000000000001531
复制
发表时间：
2018-03
期刊：
影响因子：
--
通讯作者：
Kitaoka T
中科院分区：
文献类型：
--
作者：
Matsumoto M;Suzuma K;Yamada Y;Tsuiki E;Fujikawa A;Kitaoka T
对 44 名非缺血性视网膜中央静脉阻塞 (CRVO) 患者进行了回顾性观察性病例系列研究，并通过激光散斑血流成像技术测定了视力、视网膜中央厚度和血流量。这项研究表明，玻璃体内注射贝伐珠单抗后的血流可以预测 CRVO 患者的预后。探讨玻璃体内贝伐单抗 (IVB) 治疗后视网膜血流水平是否与视网膜中央静脉阻塞继发黄斑水肿患者的预后相关。这项回顾性观察性病例研究纳入了 44 例非缺血性视网膜中央静脉阻塞病例。检查每位患者的视力、中央视网膜厚度和平均模糊率（通过激光散斑血流成像测量并代表视网膜血流速度）。随访期结束时（19.8 ± 8.8 个月），44 只眼中的 4 只（9.1%）转化为缺血型（转化组），而 40 只（90.9%）保持不变（非缺血组）。各组在第一次IVB注射后1个月，平均中央视网膜厚度显着下降，平均视力显着提高。非缺血组的平均模糊率显着增加，而转换组则没有变化。在第一次 IVB 注射后，两组之间的差异已经很显着。随后，转化组的视力恶化。多元线性回归分析表明，最近视力与最近平均模糊率之间的相关性最强。血流量测量对于评估 IVB 治疗非常有用。 IVB 后的血流量可以预测视网膜中央静脉阻塞患者的预后。
A retrospective observational case series study of 44 nonischemic central retinal vein occlusion (CRVO) patients was conducted and visual acuity, central retinal thickness, and blood flow were determined via the use of laser speckle flowgraphy. This study shows that blood flows after intravitreal bevacizumab can predict outcomes in patients with CRVO. To investigate whether retinal blood flow levels after intravitreal bevacizumab (IVB) treatment are correlated with the outcomes of patients with macular edema secondary to central retinal vein occlusion. This retrospective observational case study enrolled 44 cases nonischemic central retinal vein occlusion. In each patient, visual acuity, central retinal thickness, and mean blur rate, which was measured by laser speckle flowgraphy and represents retinal blood flow velocity, were examined. At the end of the follow-up period (19.8 ± 8.8 months), 4 of 44 eyes (9.1%) converted to the ischemic type (converted group), whereas 40 (90.9%) remained unchanged (nonischemic group). Mean central retinal thickness significantly decreased and mean visual acuity significantly improved at 1 month after the first IVB injection in each group. Mean mean blur rate in the nonischemic group significantly increased, whereas it was unchanged in the converted group. The difference between the two groups was already significant after the first IVB injection. Subsequently, visual acuity worsened in the converted group. Multiple linear regression analysis indicated that the strongest correlation was between the last visual acuity and the last mean blur rate. Blood flow measurements are useful for evaluating IVB treatments. Blood flow after IVB can predict outcomes in patients with central retinal vein occlusion.